Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.

In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D). Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time. Questionnaires were used to collect information about adverse events and ease of use of NG. In the efficacy analysis population, 69 patients experienced 157 HEs. In 95.7% patients, HEs resolved within 30 minutes of NG administration. In all the 12 severe HEs, patients awakened or returned to normal status within 15 minutes of NG administration without additional external medical help. Most caregivers reported that NG was easy to use. Most adverse events were local and of low to moderate severity. In this study, a single, 3-mg dose of NG demonstrated real-life effectiveness in treating moderate and severe HEs in adults with T1D. NG was well tolerated and easy to use.

The contribution of visceral adiposity and mid-thigh fat-rich muscle to the metabolic profile in postmenopausal women.

This study explored the relationship between muscle fat infiltration derived from mid-thigh computed tomography (CT) scan, central fat distribution and insulin sensitivity in postmenopausal women. Mid-thigh CT scans were used to measure low attenuation muscle surface (LAMS) (0-34 Hounsfield units (HU)), which represented a specific component of fat-rich muscle. Whole-body insulin sensitivity (M/I) was evaluated by an euglycemic-hyperinsulinemic clamp. A group of 103 women aged 57.0 ± 4.4 years was studied. Women with higher levels of LAMS presented higher metabolic risk features, particularly elevated fasting, 2-h plasma glucose (2hPG) concentrations and diminished M/I (P < 0.05). To further study the contribution of muscle fat infiltration and central adiposity on metabolic parameters, we divided the whole group based on the median of LAMS and visceral adipose tissue (VAT). As expected, the best metabolic profile was found in the Low-LAMS/Low-VAT group and the worst in the High-LAMS/High-VAT group. Women with Low-LAMS/High-VAT presented similar metabolic risks to those with High-LAMS/High-VAT. There was no difference between High-LAMS/Low-VAT and Low-LAMS/Low-VAT, which presents the most healthy metabolic and glycemic profiles as reflected by the lowest levels of cardiovascular disease risk variables. This suggests that High-LAMS/Low-VAT is also at low risk of metabolic deteriorations and that High-LAMS, only in the presence of High-VAT seems associated with deteriorated risks. Although increased mid-thigh fat-rich muscle was related to a deteriorated metabolic profile, VAT appears as a more important contributor to alterations in the metabolic profile in postmenopausal women.